Paul D O'Dowd, Andres S Guerrero, Katelyn R Alley, Hannah C Pigg, Fiona O'Neill, Justine Meiller, Chloe Hobbs, Daniel A Rodrigues, Brendan Twamley, Finbarr O'Sullivan, Victoria J DeRose, Darren M Griffith
It is well established that oxaliplatin, one of the three Pt(II) anticancer drugs approved worldwide, and phenanthriplatin, an important preclinical monofunctional Pt(II) anticancer drug, possess a different mode of action from that of cisplatin and carboplatin, namely, the induction of nucleolar stress. The exact mechanisms that lead to Pt-induced nucleolar stress are, however, still poorly understood. As such, studies aimed at better understanding the biological targets of both oxaliplatin and phenanthriplatin are urgently needed to expand our understanding of Pt-induced nucleolar stress and guide the future design of Pt chemotherapeutics...
March 14, 2024: ACS Chemical Biology